ARVN insider transaction filings
ARVINAS, INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-26. Screen ARVN transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 7 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing by 1 insider — 5,696 shares, $46,474 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 12.
- Largest priced transaction: sale of 5,696 shares @ $8.16 ($46,474) by Saik Andrew, filed 2026-06-24.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Saik Andrew — Chief Financial Officer | 1 | — | 1 leg · 5,696 sh · $46,474 | — |
| Bain Linda — Director | 1 | — | — | 2 |
| Cunningham Everett — Director | 1 | — | — | 2 |
| Kennedy Edward Moore Jr. — Director | 1 | — | — | 2 |
| Morrison Briggs — Director | 1 | — | — | 2 |
| Norwalk Leslie V — Director | 1 | — | — | 2 |
| Smaldone Alsup Laurie — Director | 1 | — | — | 2 |
Recent Form 4 filings — ARVINAS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-26 | 4 | Kennedy Edward Moore Jr. — Director | Grant/award (A): 15,527 @ $0 · Grant/award (A): 22,714 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Morrison Briggs — Director | Grant/award (A): 15,527 @ $0 · Grant/award (A): 22,714 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Smaldone Alsup Laurie — Director | Grant/award (A): 15,527 @ $0 · Grant/award (A): 22,714 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Bain Linda — Director | Grant/award (A): 15,527 @ $0 · Grant/award (A): 22,714 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Cunningham Everett — Director | Grant/award (A): 15,527 @ $0 · Grant/award (A): 22,714 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Norwalk Leslie V — Director | Grant/award (A): 15,527 @ $0 · Grant/award (A): 22,714 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Saik Andrew — Chief Financial Officer | Sale (S): 5,696 @ $8.16 | EDGAR |
| 2026-06-18 | 4 | Cacace Angela M — Chief Scientific Officer | Sale (S): 2,576 @ $7.59 | EDGAR |
| 2026-05-22 | 4 | Teel Randy — President and CEO, Director | Sale (S): 2,209 @ $9.04 | EDGAR |
| 2026-05-13 | 4 | Loomis David K — VP, Chief Accounting Officer | Sale (S): 1,919 @ $9.94 | EDGAR |
| 2026-05-13 | 4 | Cacace Angela M — Chief Scientific Officer | Sale (S): 9,657 @ $9.94 | EDGAR |
| 2026-05-13 | 4 | Teel Randy — President and CEO, Director | Sale (S): 9,657 @ $9.94 | EDGAR |
| 2026-05-13 | 4 | Saik Andrew — Chief Financial Officer | Sale (S): 11,139 @ $9.94 | EDGAR |
| 2026-05-13 | 4 | Berkowitz Noah — Chief Medical Officer | Sale (S): 11,108 @ $9.94 | EDGAR |
| 2026-03-19 | 4 | Berkowitz Noah — Chief Medical Officer | Sale (S): 6,435 @ $11.10 | EDGAR |
| 2026-03-12 | 4/A | Teel Randy — President and CEO, Director | Grant/award (A): 147,179 @ $0 | EDGAR |
| 2026-03-09 | 4 | Morrison Briggs — Director | Purchase (P): 20,000 @ $13.40 | EDGAR |
| 2026-03-02 | 4 | Loomis David K — VP, Chief Accounting Officer | Grant/award (A): 12,420 @ $0 · Grant/award (A): 18,504 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Cacace Angela M — Chief Scientific Officer | Grant/award (A): 45,000 @ $0 · Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Teel Randy — President and CEO, Director | Grant/award (A): 147,791 @ $0 · Grant/award (A): 218,691 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Houston John G — Director | Sale (S): 4,688 @ $13.24 · Sale (S): 18,822 @ $13.24 · Sale (S): 11,787 @ $13.14 | EDGAR |
| 2026-03-02 | 4 | Saik Andrew — Chief Financial Officer | Grant/award (A): 45,000 @ $0 · Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Berkowitz Noah — Chief Medical Officer | Grant/award (A): 45,000 @ $0 · Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2026-02-25 | 4 | Loomis David K — Chief Accounting Officer | Sale (S): 1,108 @ $12.16 | EDGAR |
| 2026-02-25 | 4 | Cacace Angela M — Chief Scientific Officer | Sale (S): 1,038 @ $12.16 · Sale (S): 2,571 @ $12.16 | EDGAR |
| 2026-02-25 | 4 | Teel Randy — President and CEO, Director | Sale (S): 1,038 @ $12.16 · Sale (S): 3,748 @ $12.16 | EDGAR |
| 2026-02-18 | 4 | Teel Randy — President and CEO, Director | Sale (S): 4,403 @ $11.89 | EDGAR |
| 2026-02-18 | 4 | Cacace Angela M — Chief Scientific Officer | Sale (S): 4,592 @ $11.89 | EDGAR |
| 2026-02-18 | 4 | Loomis David K — Chief Accounting Officer | Sale (S): 1,016 @ $11.89 | EDGAR |
| 2026-02-18 | 4 | Saik Andrew — Chief Financial Officer | Sale (S): 5,134 @ $11.89 | EDGAR |
| 2026-02-18 | 4 | Berkowitz Noah — Chief Medical Officer | Sale (S): 5,685 @ $11.89 | EDGAR |
| 2025-11-07 | 4 | Loomis David K — Chief Accounting Officer | Sale (S): 230 @ $9.89 | EDGAR |
| 2025-09-24 | 4 | Morrison Briggs — Director | Purchase (P): 30,000 @ $7.57 | EDGAR |
| 2025-06-30 | 4 | AGARWAL SUNIL — Director | Grant/award (A): 16,025 @ $0 · Grant/award (A): 23,105 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Kennedy Edward Moore Jr. — Director | Grant/award (A): 16,025 @ $0 · Grant/award (A): 23,105 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Morrison Briggs — Director | Grant/award (A): 16,025 @ $0 · Grant/award (A): 23,105 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Smaldone Alsup Laurie — Director | Grant/award (A): 16,025 @ $0 · Grant/award (A): 23,105 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Bain Linda — Director | Grant/award (A): 16,025 @ $0 · Grant/award (A): 23,105 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Cunningham Everett — Director | Grant/award (A): 16,025 @ $0 · Grant/award (A): 23,105 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | YOUNG JOHN D — Director | Grant/award (A): 16,025 @ $0 · Grant/award (A): 23,105 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Norwalk Leslie V — Director | Grant/award (A): 16,025 @ $0 · Grant/award (A): 23,105 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Saik Andrew — Chief Financial Officer | Sale (S): 5,700 @ $7.61 | EDGAR |
| 2025-06-18 | 4 | Cacace Angela M — Chief Scientific Officer | Sale (S): 2,583 @ $7.49 | EDGAR |
| 2025-05-13 | 4 | Loomis David K — Chief Accounting Officer | Grant/award (A): 11,825 @ $0 · Grant/award (A): 18,100 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | Cacace Angela M — Chief Scientific Officer | Grant/award (A): 59,600 @ $0 · Grant/award (A): 91,000 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | Saik Andrew — Chief Financial Officer | Grant/award (A): 59,600 @ $0 · Grant/award (A): 91,000 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | Berkowitz Noah — Chief Medical Officer | Grant/award (A): 59,600 @ $0 · Grant/award (A): 91,000 (derivative) @ $0 | EDGAR |
| 2025-03-19 | 4 | Berkowitz Noah — Chief Medical Officer | Sale (S): 8,658 @ $8.59 | EDGAR |
| 2025-02-25 | 4 | Taylor Ian — President, R&D | Sale (S): 7,356 @ $16.75 · Sale (S): 1,664 @ $16.55 | EDGAR |
| 2025-02-25 | 4 | Houston John G — President and CEO, Director | Sale (S): 26,184 @ $16.75 · Sale (S): 5,154 @ $16.55 | EDGAR |
Recent 8-K events — ARVINAS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-25 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-16 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-02 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-01 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-18 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-24 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ARVN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →